NCT06457906View on ClinicalTrials.gov

SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC

PHASE3RecruitingINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

August 30, 2027

Study Completion Date

February 28, 2028

Conditions
Small-cell Lung CancerBrain MetastasesSRSStereotactic RadiotherapyWhole Brain RadiotherpayHippocampal-avoidance
Interventions
COMBINATION_PRODUCT

Experimental group (SRS/SRT/Hypo-RT)

The prescription dose of SRS/SRT is 18-22Gy in 1 fraction, 27Gy in 3 fractions and 30Gy in 5 fractions. The prescription dose of Hypo-RT is 40Gy in 8 fraction. The prescription dose could be adjusted if lesions are located in brain stem when treat with SRS/SRT/Hypo-RT.

RADIATION

Controled group (HA-WBRT)

The prescription dose of HA-WBRT is 30Gy in 10 fraction.

Trial Locations (1)

100021

RECRUITING

Nan Bi, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER